From: A mini-whole lung lavage to treat autoimmune pulmonary alveolar proteinosis (PAP)
Study group [n = 7] | Control group [n = 6] | ||
---|---|---|---|
Age, years [mean ± SD] | 42.7 ± 16 | 53.3 ± 9.4 | |
Ratio male/female | 4/3 | 3/3 | |
Smoking status [n (%)] | |||
Current | 1 (14.28%) | 1 (16.66%) | |
Previous | 2 (28.57%) | 3 (50.00%) | |
Never | 4 (57.14%) | 2 (33.33%) | |
Symptoms at diagnosis [n (%)] | |||
Dyspnoea | 5 (71.42%) | 5 (83.33%) | |
Cough | 5 (71.42%) | 4 (66.66%) | |
Fever | 2 (28.57%) | – | |
Fatigue | 2 (28.57%) | – | |
Biomarkers [mean ± SD] | |||
Cyfra 21.1 (ng/mL) | 11.85 ± 8.7 | 16 ± 11.26 | (nv: 0.0–3.3) |
CEA (ng/mL) | 13.71 ± 13.46 | 18 ± 20.07 | (nv: 0.0–5.0) |
NSE (ng/mL) | 24 ± 11.60 | 21.33 ± 14.19 | (nv: 0.0–15.0) |
GMAbs (μg/mL) | 108.44 ± 80.33 | 216.20 ± 263.63 | (nv < 3) |
Infection at diagnosis [n (%)] | 4 (57.14%) | 3 (50.00%) | |
Time to diagnosis, months [mean (range)] | 7 (1–23) | 4 (0–16) | |
1° lung flooding time, minutes [mean ± SD] | 34 ± 8 | 50 ± 8 | |
2° lung flooding time, minutes [mean ± SD] | 29 ± 2 | 48 ± 9 |